Union européenne - slovaque - EMA (European Medicines Agency)

n.v. organon - nomegestrol acetát, estradiol - antikoncepcie - pohlavné hormóny a modulátory z genitálny systém, - orálna antikoncepcia.

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bayer ag - levonorgestrel a estrogény - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bayer ag - moxifloxacín - 42 - chemotherapeutica (vratane tuberkulostatik)

Union européenne - slovaque - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - propafenón - 13 - antiarrythmica

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - amoxicilín a inhibítor betalaktamázy - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - amoxicilín a inhibítor betalaktamázy - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)

Slovaquie - slovaque - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - propafenón - 13 - antiarrythmica

Union européenne - slovaque - EMA (European Medicines Agency)

viiv healthcare b.v. - maravirok - hiv infekcie - antivirotiká na systémové použitie - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.

Union européenne - slovaque - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotické činidlá - akútna koronárna syndromemyocardial myokardu.